Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle
Manipulating the complex interaction between the immune system and tumour cells has been the focus of cancer research for many years, but it is only in the past decade that significant progress has been made in the field of cancer immunotherapy resulting in clinically effective treatments. The block...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
European Medical Journal
2015-03-01
|
Series: | European Medical Journal Oncology |
Subjects: | |
Online Access: | http://emjreviews.com/wp-content/uploads/Checkpoint-Blockade-in-Cancer-Immunotherapy-Squaring-the-Circle.pdf |
id |
doaj-2b64ed043eb74697afd411590f0e9d98 |
---|---|
record_format |
Article |
spelling |
doaj-2b64ed043eb74697afd411590f0e9d982020-11-25T00:46:41ZengEuropean Medical JournalEuropean Medical Journal Oncology2054-619X2015-03-01317076Checkpoint Blockade in Cancer Immunotherapy: Squaring the CircleMaria A.V. Marzolini0Sergio A. Quezada1Karl S. Peggs2 Cancer Institute, University College London, London, UK Cancer Institute, University College London, London, UK Cancer Institute, University College London, London, UK Manipulating the complex interaction between the immune system and tumour cells has been the focus of cancer research for many years, but it is only in the past decade that significant progress has been made in the field of cancer immunotherapy resulting in clinically effective treatments. The blockade of co-inhibitory immune checkpoints, essential for maintaining lymphocyte homeostasis and self-tolerance, by immunomodulatory monoclonal antibodies has resulted in the augmentation of anti-tumour responses. The greatest successes so far have been seen with the blockade of cytotoxic T lymphocyte associated antigen-4, which has resulted in the first Phase III clinical trial showing an overall survival benefit in metastatic melanoma, and in the blockade of the programmed cell death protein-1 axis. This concise review will focus on the clinical advances made by the blockade of these two pathways and their role in current cancer treatment strategies. http://emjreviews.com/wp-content/uploads/Checkpoint-Blockade-in-Cancer-Immunotherapy-Squaring-the-Circle.pdfCancer immunotherapycytotoxic T lymphocyte associated antigen-4 (CTLA-4)programmed cell death protein-1 (PD-1)programmed death ligand-1 (PD-L1) |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Maria A.V. Marzolini Sergio A. Quezada Karl S. Peggs |
spellingShingle |
Maria A.V. Marzolini Sergio A. Quezada Karl S. Peggs Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle European Medical Journal Oncology Cancer immunotherapy cytotoxic T lymphocyte associated antigen-4 (CTLA-4) programmed cell death protein-1 (PD-1) programmed death ligand-1 (PD-L1) |
author_facet |
Maria A.V. Marzolini Sergio A. Quezada Karl S. Peggs |
author_sort |
Maria A.V. Marzolini |
title |
Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle |
title_short |
Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle |
title_full |
Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle |
title_fullStr |
Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle |
title_full_unstemmed |
Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle |
title_sort |
checkpoint blockade in cancer immunotherapy: squaring the circle |
publisher |
European Medical Journal |
series |
European Medical Journal Oncology |
issn |
2054-619X |
publishDate |
2015-03-01 |
description |
Manipulating the complex interaction between the immune system and tumour cells has been the focus of cancer research for many years, but it is only in the past decade that significant progress has been made in the field of cancer immunotherapy resulting in clinically effective treatments. The blockade of co-inhibitory immune checkpoints, essential for maintaining lymphocyte homeostasis and self-tolerance, by immunomodulatory monoclonal antibodies has resulted in the augmentation of anti-tumour responses. The greatest successes so far have been seen with the blockade of cytotoxic T lymphocyte associated antigen-4, which has resulted in the first Phase III clinical trial showing an overall survival benefit in metastatic melanoma, and in the blockade of the programmed cell death protein-1 axis. This concise review will focus on the clinical advances made by the blockade of these two pathways and their role in current cancer treatment strategies.
|
topic |
Cancer immunotherapy cytotoxic T lymphocyte associated antigen-4 (CTLA-4) programmed cell death protein-1 (PD-1) programmed death ligand-1 (PD-L1) |
url |
http://emjreviews.com/wp-content/uploads/Checkpoint-Blockade-in-Cancer-Immunotherapy-Squaring-the-Circle.pdf |
work_keys_str_mv |
AT mariaavmarzolini checkpointblockadeincancerimmunotherapysquaringthecircle AT sergioaquezada checkpointblockadeincancerimmunotherapysquaringthecircle AT karlspeggs checkpointblockadeincancerimmunotherapysquaringthecircle |
_version_ |
1725263760484990976 |